Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Keld Kjeldsen; Henning Bundgaard

doi:10.1111/j.1749-6632.2003.tb07285.x

Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Keld Kjeldsen^*, Henning Bundgaard

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

Abstract

The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

Original language	English
Pages (from-to)	702-707
Number of pages	6
Journal	Annals of the New York Academy of Sciences
Volume	986
DOIs	https://doi.org/10.1111/j.1749-6632.2003.tb07285.x
Publication status	Published - 1 Jan 2003

Keywords

Digoxin
Heart failure
Na,K-ATPase

Access to Document

10.1111/j.1749-6632.2003.tb07285.x

Cite this

@article{66dbef7ddd1245f18e485fc6236f4671,

title = "Myocardial Na,K-ATPase and digoxin therapy in human heart failure",

abstract = "The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.",

keywords = "Digoxin, Heart failure, Na,K-ATPase",

author = "Keld Kjeldsen and Henning Bundgaard",

year = "2003",

month = jan,

day = "1",

doi = "10.1111/j.1749-6632.2003.tb07285.x",

language = "English",

volume = "986",

pages = "702--707",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Myocardial Na,K-ATPase and digoxin therapy in human heart failure

AU - Kjeldsen, Keld

AU - Bundgaard, Henning

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

AB - The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

KW - Digoxin

KW - Heart failure

KW - Na,K-ATPase

UR - http://www.scopus.com/inward/record.url?scp=0037564210&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2003.tb07285.x

DO - 10.1111/j.1749-6632.2003.tb07285.x

M3 - Article

C2 - 12763921

AN - SCOPUS:0037564210

SN - 0077-8923

VL - 986

SP - 702

EP - 707

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this